4-Hydroxybenzaldehyde

4-Hydroxybenzaldehyde

SCHEMBL6942477

O=Cc1ccc(O)cc1.c1cc2cc(c1)OC2

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH5A1 P51649 1/20 0.50
ABAT P80404 1/20 0.50
KMT2A Q03164 2/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
MIF P14174 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
GSK3B P49841 2/20 0.35
MAOB P27338 2/20 0.35
MEN1 O00255 1/20 0.35
ACHE P22303 1/20 0.35
JAK2 O60674 3/20 0.34
JAK1 P23458 3/20 0.34
TYK2 P29597 3/20 0.34
JAK3 P52333 3/20 0.34
KDM4E B2RXH2 2/20 0.34
PTGS2 P35354 1/20 0.34
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 2/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3-Hydroxybenzaldehyde SCHEMBL9842145 0.86 CCNB2 (0.42) KMT2AMAOBMEN1KDM4EALDH1A1
SCHEMBL9761005 0.81 KDM4E (0.40) ALDH5A1ABATKMT2ATDP1MEN1
Anisaldehyde SCHEMBL6586624 0.81 ALDH1A1 (0.54) KMT2ATDP1MAOBMEN1RAB9A
Salicyladehyde SCHEMBL6290054 0.78 TRIM24 (0.56) KMT2ATDP1MEN1JAK2JAK1
4-Hydroxybenzaldehyde SCHEMBL10429027 0.76 ALDH1A1 (0.44) ALDH5A1ABATKMT2AESR1ESR2
SCHEMBL27694314 0.75 JAK2 (0.42) JAK2JAK1TYK2JAK3
Propene SCHEMBL27830749 0.74 JAK2 (0.36) JAK2JAK1TYK2JAK3
4-Hydroxybenzaldehyde SCHEMBL7168177 0.73 ALDH5A1 (0.76) ALDH5A1ABATKMT2AESR1ESR2
4-Hydroxybenzaldehyde SCHEMBL27689568 0.72 ALDH5A1 (0.67) ALDH5A1ABATKMT2AESR1ESR2
3-Hydroxybenzaldehyde SCHEMBL6269860 0.72 CCNB2 (0.44) KMT2AMAOBMEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103539642-A Method for preparing 3,4,5-trimethoxy-3'-hydroxy-4'-alkoxy diphenylethane SHANGHAI INST TECHNOLOGY 2014-01-29 CN claimed
EP-4458916-A1 PHOTOCATALYTICALLY ACTIVE COATING COMPOSITION, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF TriOptoTec GmbH (DE) 2024-11-06 EP disclosed
CN-110294732-A Medical compounds and its application for treating hepatopathy 江苏新元素医药科技有限公司 2019-10-01 CN disclosed
CN-103539642-A Method for preparing 3,4,5-trimethoxy-3'-hydroxy-4'-alkoxy diphenylethane SHANGHAI INST TECHNOLOGY 2014-01-29 CN disclosed
CN-101829098-B Application of substituted isosilybin in preparing medicament for treating virus hepatitis B UNIV DALI 2012-10-17 CN disclosed
CN-1898240-B Imidazopyrazine tyrosine kinase inhibitors OSI PHARM INC 2011-08-03 CN disclosed
CN-101829098-A Application of substituted isosilybin in preparing medicament for treating virus hepatitis B UNIV DALI 2010-09-15 CN disclosed
CN-1898240-A Imidazopyrazine tyrosine kinase inhibitors OSI PHARM INC (US) 2007-01-17 CN disclosed
EP-1121338-A4 METHOD FOR SYNTHESIZING DIARYL-SUBSTITUTED HETEROCYCLIC COMPOUNDS, INCLUDING TETRAHYDROFURANS MILLENNIUM PHARM INC (US) 2003-03-12 EP disclosed
US-20020128491-A1 Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans RAO ALLA VENKATA RAMA (IN) 2002-09-12 US disclosed
US-6403814-B1 REACTING WITH GRIGNARD REAGENT COMPOUND HAVING CARBON SUBSTITUTED BY ACETYLENE GROUP, ARYL GROUP AND HYDROXYL GROUP, HYDROGENATING ACETYLENE MOIETY OF REACTION PRODUCT, CYCLIZING TO PROVIDE DI-ARYL TETRAHYDROFURAN MILLENNIUM PHARMACEUTICALS, INC. 2002-06-11 US disclosed
EP-1121338-A1 METHOD FOR SYNTHESIZING DIARYL-SUBSTITUTED HETEROCYCLIC COMPOUNDS, INCLUDING TETRAHYDROFURANS Millennium Pharmaceuticals, Inc. (US) 2001-08-08 EP disclosed
WO-2000023409-A1 METHOD FOR SYNTHESIZING DIARYL-SUBSTITUTED HETEROCYCLIC COMPOUNDS, INCLUDING TETRAHYDROFURANS LEUKOSITE, INC. (US) 2000-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128491-A1 Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans TPMT, TPI1, GTF2I ALDH5A1 883/4885ABAT 1343/4885KMT2A 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.